Exploiting the CXCR3/CXCL10 axis overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in HNSCC
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2522360123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Cheyanne K Shinn und 5 weiteren Autor:innen. Beteiligte Einrichtung: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093. Hauptthemen laut MEDLINE: Chemokine CXCL10, Receptors, CXCR3, Head and Neck Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Institute of Dental and Craniofacial Research (NIDR), Moores Cancer Center, UC San Diego Health (MCC), NIDCR NIH HHS.
Abstract (Originalsprache)
Immune-suppressive tumor microenvironments (TMEs) limit the impact of checkpoint blockade in many cancers by restricting the infiltration and activation of CD8 + T, CD4 + T, and NK cells. Utilizing murine models of head and neck squamous cell carcinoma, we demonstrated that intratumoral (IT) delivery of CXCL10 drives tumor elimination and inhibits recurrence not only by recruiting these cells but by enhancing their antitumoral functions and stunting angiogenesis. CD8 + T cells also display enhanced activation, tumor-antigen specificity, and decreased T cell exhaustion. Despite administration of CXCL10 into tumors, CD8 + and CD4 + T cells show enhanced presence and proliferation in tumor-draining lymph nodes (TdLNs), consistent with T cell priming and trafficking between tumors and TdLNs. Together, the data suggest that CXCL10 promotes a mutually reinforcing feedback loop that reprograms the TME toward an immunologically responsive antitumoral state. Combining IT-CXCL10 and anti-PD-1 further increased tumor clearance, indicating that CXCL10-driven reprogramming of the TME lowers barriers to effective checkpoint blockade.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093.
- Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093.
- Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093.
- Department of Otolaryngology-Head and Neck Surgery, University of California, San Diego, La Jolla, CA 92093.
- Gleiberman Head and Neck Cancer Center, University of California, San Diego, La Jolla, CA 92093.
ORCID-Profile: Cheyanne K Shinn, Robert Saddawi-Konefka, Shiruyeh Schokrpur, J Silvio Gutkind, Tracy M Handel
Förderung
- HHS | NIH | National Institute of Dental and Craniofacial Research (NIDR)
- Moores Cancer Center, UC San Diego Health (MCC)
- NIDCR NIH HHS
- HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- NCI NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- NIGMS NIH HHS
Zitieren
APA
Shinn, C. K., Saddawi-Konefka, R., Salanga, C. L., Schokrpur, S., Gutkind, J. S., & Handel, T. M. (2026). Exploiting the CXCR3/CXCL10 axis overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in HNSCC. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2522360123
Vancouver
Shinn CK, Saddawi-Konefka R, Salanga CL, Schokrpur S, Gutkind JS, Handel TM. Exploiting the CXCR3/CXCL10 axis overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in HNSCC. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2522360123
BibTeX
@article{Shinn2026,
author = {Shinn, Cheyanne K and Saddawi-Konefka, Robert and Salanga, Catherina L and Schokrpur, Shiruyeh and Gutkind, J Silvio and Handel, Tracy M},
title = {Exploiting the CXCR3/CXCL10 axis overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in HNSCC},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2522360123}
}
EUVIMED